Skip to main content
SpringerLink
Log in

Anastrozole

A Viewpoint by Aman U. Buzdar

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001 Sep; 7: 2620–35

    PubMed  CAS  Google Scholar 

  2. Osborne CK, Pippen J, Jones SE, et al. Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endrocrine therapy: results of a North American trial. J Clin Oncol 2002 Aug 15; 20: 3386–95

    Article  PubMed  CAS  Google Scholar 

  3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 Mar 15; 344(11): 783–92

    Article  PubMed  CAS  Google Scholar 

  4. Holmes FA, Valero V, Walters RS, et al. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr 1993; 15: 161–9

    Google Scholar 

  5. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995 Dec; 13(12): 2886–94

    PubMed  CAS  Google Scholar 

  6. NSABP. The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27 [abstract]. Breast Cancer Res Treat 2001 Oct; 69(3): 210

    Google Scholar 

  7. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002 Jun 22; 359(9324): 2131–9

    Article  Google Scholar 

  8. Henderson IC, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 101a

    Google Scholar 

  9. The ATAC Trialists’ Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the Arimidex™ and tamoxifen alone or in combination (ATAC) trial. Br J Cancer 2001 Aug 3; 85(3): 317–24

    Article  Google Scholar 

  10. Dowsett M, Poster C, Johnson SRD, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999 Sep; 5(9): 2338–43

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

    Aman U. Buzdar

Authors
  1. Aman U. Buzdar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buzdar, A.U. Anastrozole. Drugs 62, 2492 (2002). https://doi.org/10.2165/00003495-200262170-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262170-00012

Search

Navigation